BioPharmSignal logoBioPharmSignal

Biotech News

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsConference / presentation

CRANBURY, N.J. --(BUSINESS WIRE)--Jan. 5, 2026-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the Company will participate in the

Open original release

Related news

CRNXCrinetics Pharmaceuticals2026-05-22 20:05 EST

Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

KPTIKaryopharm Therapeutics2026-05-28 11:30 EST

Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference

CRBUCaribou2026-05-27 20:05 EST

Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference

ARWRArrowhead Pharmaceuticals2026-06-02 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

ARWRArrowhead Pharmaceuticals2026-05-04 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

SRPTSarepta Therapeutics2026-05-13 20:30 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

CRBUCaribou2026-05-13 20:05 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

CRSPCRISPR Therapeutics2026-05-06 12:30 EST

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference

SANASana Biotechnology2026-05-05 20:05 EST

Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference

View all latest news

Rocket Pharmaceuticals

Rocket Pharmaceuticals is a gene-therapy company focused on rare pediatric and hematologic diseases. Its story is built around using advanced genetic medicine to address severe inherited conditions.

Recent company news

RCKTRocket Pharmaceuticals2026-05-07 20:00 EST

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-04-28 11:00 EST

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

RCKTRocket Pharmaceuticals2026-03-27 11:00 EST

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

RCKTRocket Pharmaceuticals2026-02-26 21:00 EST

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

RCKTRocket Pharmaceuticals2026-02-23 12:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Stock data

Close
3.25 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States